

Medserv

FY17 results

Internationalisation underpins growth

Medserv's strategy to expand its geographic reach and range of services is bearing fruit. FY17 was affected by lower than expected demand and project delays, but Q118 results show strong progress and the order backlog underpins future revenue performance. A change of management and key shareholders at an early stage to source a strategic purchaser have also been announced. We reduce our FY18 estimates on the lower run rate out of FY17 and introduce FY19 estimates.

Year end	Revenue (€m)	PBT* (€m)	EPS* (c)	DPS (c)	P/E (x)	Yield (%)
12/16	32.8	(1.3)	(2.1)	0.0	N/A	N/A
12/17	28.8	(3.6)	(5.6)	0.0	N/A	N/A
12/18e	36.0	(1.4)	(1.4)	2.0	N/A	1.8
12/19e	39.3	2.2	4.7	2.0	23.4	1.8

Note: *PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments.

FY17 affected by demand but Q118 shows progress

Reported FY17 revenues of €28.78m (FY16 €32.82m) were slightly up against our estimate of €28.2m. However, a slowdown in end-market demand and drilling delays prompted the company to lower expectations as the year progressed. Tougher trading conditions than expected also affected profitability, with company reported adjusted EBITDA down at €4.43m (FY16 €5.40m). The reported regulatory EPS loss of 13.8c (FY16 5.9c) and no dividend were as expected. Q118 revenues of €8.3m (Q117 €7.0m) indicated a strong bounceback at Integrated Logistic Support Services (ILSS) (up 75% on Q117), although Oil Country Tubular Goods (OCTG) had a slightly weaker start (down 20% on Q117). Overall, we believe recent wins building the current order book support FY18 expectations of group revenue of €36.7m and group EBITDA of €6.8m.

Expanding services and geographic footprint

The METS acquisition in 2016 broadened the group's service portfolio to include pipe repair and supply chain management. Recent contract wins have broadened the geographic presence of the ILSS business, including a multi-site contract in Egypt that could also present an opportunity for the OCTG business. Medserv is present in eight countries and current tender activity could expand that further. It is active and profitable in six out of its seven operating bases and the company expects to build on its Q118 performance as the year progresses with further growth in FY19. While a strategic purchaser is being sought for all or part of the majority shareholding, we believe there is no time pressure and the management succession plan has been executed seamlessly.

Valuation: Momentum building

We adjust our FY18 estimates with lower top-line and profitability assumptions and introduce FY19 estimates. The new territories coming on stream support revenue growth for 2018-20 and we forecast financial performance in FY18 to support a dividend. Our DCF-based fair value stands at €1.51 per share, from €1.64 before.


Industrial support services

14 May 2018

Price €1.10
Market cap €59m

Net debt (€m) at 31 December 2017	49.2
Shares in issue	53.7m
Free float	35%
Code	MDS
Primary exchange	Malta SE
Secondary exchange	N/A

Share price performance



%	1m	3m	12m
Abs	(3.5)	(5.2)	(18.5)
Rel (local)	(1.9)	(1.3)	(11.3)
52-week high/low		€1.4	€1.1

Business description

Medserv is a Malta-based provider of integrated offshore logistics and services in support of drilling operations in the Mediterranean. The acquisition of the METS companies in February 2016 diversified the company into onshore steel tube stockholding and servicing for countries in the Middle East.

Next events

Interim results	August 2018
-----------------	-------------

Analyst

Annabel Hewson +44 (0)20 3077 5700
industrials@edisongroup.com
[Edison profile page](#)

**Medserv is a research client of
Edison Investment Research
Limited**

FY17: A year of transition

Overall, business levels in FY17 were affected by the cost-cutting focus of international oil companies (IOCs), reducing operations and delaying projects. Medserv's trading statement in November 2017 indicated that H217 earnings would be lower than forecast due to delays in both its divisions. Drilling delays at ILSS reduced the FY17 results and contributed to most of the miss. In addition, the OCTG division was subject to movement in demand, where the strong pick-up in activity seen in Iraq in Q3 did not continue into Q4, as the IOCs negotiated next steps.

Exhibit 1: Medserv H117 and FY17 financial summary


€m	H116	H216	FY16	H117	H217	FY17	FY% change
ILSS	10.6	8.7	19.3	5.8	8.2	14.0	-27%
OCTG	6.5	6.6	13.1	7.6	6.7	14.3	9%
Photovoltaic Farm	0.3	0.2	0.5	0.3	0.2	0.5	9%
Group revenues	17.3	15.5	32.8	13.6	15.2	28.8	-12%
Adj EBITDA (company defined)	3.55	1.9	5.4	1.6	2.7	4.33	-20%
EBITDA	3.43	1.5	4.95	1.39	2.3	3.67	-26%
Operating profit (reported)	1.09	1.1	0.01	(1.40)	(2.7)	(4.10)	NM
Finance costs	(0.81)	(1.7)	(2.46)	(1.50)	(2.4)	(3.94)	60%
Profit before tax (reported)	0.28	(2.73)	(2.45)	(2.90)	(5.14)	(8.04)	228%
Taxation	(0.06)	5.5	5.43	(0.55)	1.0	0.40	-93%
Net income (reported)	0.22	2.8	2.98	(3.45)	(4.2)	(7.63)	-356%
Net debt	0.16		46.95	47.22		49.21	5%

Source: Company reports

Key figures to note:

- **Reported revenues** of €28.78m (FY16 €32.82m), against our estimate of €28.2m. In April 2017, the company forecast FY17 revenues of €35.94m; however, the slowdown in demand and drilling delays prompted the company to lower expectations as the year progressed. The tougher than expected trading conditions also affected profitability.
- **Company reported adjusted EBITDA** of €4.43m (FY16 €5.40m), against our estimate of €4.2m.
- **Regulatory EPS loss** of 13.8c (FY16 5.9c).
- No dividend.

Exhibit 2: FY17 revenue by major service line



Source: Company reports

ILSS

ILSS reported FY17 revenues of €13.97m, down from €19.25m in FY16. Fundamentally, the division was affected by the cost-cutting focus of IOCs reducing operations and delaying projects.

However, FY18 revenue forecasts in ILSS are supported by growth prospects across a number of geographies.

The key growth driver for the division is Cyprus, where drilling began in Q417. As a reminder, ENI is the leading offshore IOC operating in the Mediterranean and Medserv supports its drilling operations in Cyprus from its onshore bases in Larnaca and Limassol. The Calypso lean gas discovery offshore Cyprus announced by ENI earlier this year is believed to be 'Zohr-like'; Zohr, offshore Egypt, is the largest gas field in the Mediterranean. ENI has a 50% participation in Block 6 where the new find has been made and Medserv's ILSS business recommenced support for the drilling programme in Q417. The new find should provide an extended drilling programme, offering greater visibility and improved returns from Cyprus. To date, Medserv has provided services to ENI from its new Limassol base (full operation) and its storage facility in Larnaca. However, Medserv has taken the decision to consolidate its operations in Cyprus at Limassol. It has also tendered for the provision of services to a second IOC operating in the region, which is at an advanced stage.

Looking forward, Medserv is engaged in advanced negotiations to locate support bases in new geographical regions that should support longer-term growth. The company has indicated that contracts here would be focused on development and production rather than exploration. Medserv announced on 23 January that it had secured business, via a competitive tender, in "a market, considered by the industry to be the big new energy source on Europe's doorstep", which the company now discloses as Egypt. The three-year c €10m contract to provide integrated logistics support services for the production phase of offshore has an option to extend. In the future, Medserv could build OCTG opportunities into the offering in country.

Both ENI and the Egyptian authorities regard the Zohr gas field as a priority for development. The proximity of the field to the Cyprus blocks is a key driver of the renewed drilling activity there. In addition, the expectation that rigs will be prioritised to these programmes has led to the further deferral of the wildcat drilling programme offshore Portugal, where the licence runs to early 2019. Therefore, Portugal is expected to deliver relatively flat performance in the short term. Meanwhile, the company has secured extensions to contracts for offshore Libya. In the region, ENI's strategy for the A and E structures in Bahr Essalam should require increased production support, which should in turn provide a boost to the Malta-base towards the end of the year.

OCTG

OCTG reported FY17 revenues of €14.28m up from €13.08m in FY16. Oman saw a 15% uplift in tonnage supported by the new long-term Sumitomo supply chain contract win in the year. Continuing with the consolidation theme, it is possible the company will consolidate its facilities with the newly opened Duqm in the central Eastern region and Sohar in the North, although this will depend on end-market demand. FY17 was broadly flat for Medserv in the United Arab Emirates, however orders have picked up for the premium threading activity building visibility in this area. Iraq has been impacted by domestic issues and the weakness was visible in Q118. However, the number of land rigs mobilised in country and the current order book suggest activity levels will improve.

While the contribution from Oman is expected to remain stable the UAE should see a small improvement; hence we have made modest adjustments to our estimates for this division. In addition, the company is working hard to secure business in new regions. Medserv has entered a tender for the provision of machine shop services in Uganda, which as a long-term contract could bring greater visibility to the division and predictability to its financial performance.

Photovoltaic Farm (PV)

PV reported FY17 revenues of €0.53m up from €0.49m in FY16. Looking forward, FY18 revenue is expected to remain flat year-on-year.

Outlook

Medserv has reported Q118 revenue and EBITDA performance. FY18 has started strongly for ILSS and although OCTG had a weaker start, we believe the current order book supports FY18 expectations. Medserv is active and profitable in six out of its seven operating bases and expects the company to build on its Q118 performance as the year progresses, with further growth in FY19.

Exhibit 3: Q118 reported and Medserv FY18 estimates for revenue and EBITDA						
€m	Q117	Q118	% change	FY17	Medserv's FY18 outlook	% change
ILSS	2.8	4.9	75	14.0	18.4	31
OCTG	4.1	3.3	(20)	14.3	17.8	24
Photovoltaic Farm	0.1	0.1	0	0.5	0.5	0
Group revenues	7.0	8.3	19	28.8	36.7	27
Group EBITDA	0.9	1.40	56	4.4	6.8	55
EBITDA margin (%)	12.9	16.9	31	15.3	18.5	198.8
Source: Company reports						

Although FY17 presented a number of challenges to the oil & gas industry, Medserv sees strong projected growth over 2018 to 2020. The business is working tirelessly in each of its divisions to build its geographic presence and deliver technical expertise. Project timing was challenging in Q417; however, the overall direction of travel seen in Q118 and for FY18 remains good. Additional contracts added in Q118 underpin expectations and build addressable markets. Stronger group performance should allow dividend payments to return and we have included this in our forecasts.

The company's FY17 report states "The outlook for the group remains optimistic, as the group anticipates better performance in all its operating segments as the market continues to improve over the year."

Medserv has announced some management changes. Karl Bartolo has been appointed chief executive officer; Karl previously held the role of chief financial officer and has been CEO designate since July 2016. Silvio Camilleri has been appointed chief financial officer after joining Medserv in February 2017 as group financial controller. Anthony Diacono will continue to chair the board of directors; however, Anthony Diacono and executive director Anthony Duncan, beneficial owner of Malampaya Investments, have announced their intention to source a strategic purchaser for all or part for their shareholdings (in total 65.5% of issued share capital). The process is at a very early stage and it is important to note there is no time or financial pressure to sell. In addition, the management succession plan has been carefully thought through.

Estimate revisions, valuation implications

We have revised our estimates for the group and introduced FY19 estimates. As activity increases the operational leverage should allow a rapid recovery in profitability. The increase in drilling programmes and workover projects seen in H217 has provided operational momentum into FY18. In addition, as the company secures business in new geographic markets this will support growth and build visibility for the medium term. We see operating leverage from the improved business activity levels, which in turn should support improved cash generation. We expect improving margin performance as the year progresses, with H218 operations increased drilling activity and greater overhead recovery. However, we have reduced the pace at which this is delivered. As we mentioned earlier, stronger group performance should allow dividend payments to return and we have this in our forecasts, albeit slightly reduced from prior levels to reflect the lower profit contribution.

The group adopted IFRS15 and IFRS16 with its FY17 report. There was limited impact from the IFRS15 introduction. However, IFRS16 adoption prompted a fair value exercise to be carried out for

the industrial property rights over the land under the lease agreements, which resulted in a revaluation increase of €16.96m recognised in other comprehensive income. Going forward, we have reduced our property rental cost assumptions to zero while increasing the depreciation charge and other financial costs to reflect the adopted standard.

Exhibit 4: Medserv estimate revisions

Year to December (€m)	2017			2018e			2019e
	Estimated	Reported	% change	Old	New	% change	New
Revenues	28.2	28.8	2	42.3	36.0	(14.8)	39.3
EBITDA	3.4	3.7	8.8	12.5	6.5	(48.3)	10.5
Profit before tax (normalised)	(2.8)	(3.6)		5.8	(1.4)		2.2
EPS - normalised (c)	(6.4)	(5.6)		9.5	(1.4)		4.7
DPS (c)	0.0	0.0		3.8	2.0	(47.4)	2.0
Net debt	46.6	49.2	(5.1)	48.7	54.6	(12.1)	53.2

Source: Edison Investment Research

We continue to employ a capped DCF approach to valuation, which encompasses a six-year explicit forecast projection with a zero growth scenario anticipated in our terminal value calculation. We have used a cost of equity of 11%, which gives us a calculated WACC of 8.2%. Our core assumptions return a DCF value of €1.51 per share, down from €1.64 per share. While our reduced forecasts have affected the valuation, they present upside to the current share price to reflect the growth prospects of the business.

Exhibit 5: Financial summary

	€m	2015	2016	2017	2018e	2019e
Year end 31 December		IFRS	IFRS	IFRS	IFRS	IFRS
PROFIT & LOSS						
Revenue		42.7	32.8	28.8	36.0	39.3
Cost of Sales		(29.9)	(22.9)	(18.2)	(21.8)	(22.9)
Gross Profit		12.8	9.9	10.6	14.2	16.4
EBITDA		10.3	5.0	3.7	6.5	10.5
Operating Profit (before amort. and except.)		7.6	1.6	(1.2)	1.6	5.4
Intangible Amortisation		0.0	0.0	0.0	0.0	0.0
Exceptionals		(0.1)	(1.2)	(4.501)	(3.2)	(3.1)
Other		(0.2)	0.0	0.0	0.0	0.0
Operating Profit		7.3	0.4	(5.7)	(1.6)	2.3
Net Interest		(1.5)	(2.8)	(2.4)	(3.1)	(3.3)
Profit Before Tax (norm)		6.1	(1.3)	(3.6)	(1.4)	2.2
Profit Before Tax (FRS 3)		5.8	(2.5)	(8.1)	(4.6)	(0.9)
Tax		(1.3)	5.4	0.4	0.5	0.1
Profit After Tax (norm)		4.8	4.1	(3.2)	(1.0)	2.3
Profit After Tax (FRS 3)		4.5	3.0	(7.7)	(4.2)	(0.9)
Average Number of Shares Outstanding (m)		46.1	52.8	53.7	53.7	53.7
EPS - normalised (c)		9.7	(2.1)	(5.6)	(1.4)	4.7
EPS - normalised and fully diluted (c)		9.7	(2.1)	(5.6)	(1.4)	4.7
EPS - (IFRS) (c)		8.9	5.9	(14.0)	(7.3)	(1.2)
Dividend per share (c)		4.3	0.0	0.0	2.0	2.0
Gross Margin (%)		30.1	30.2	36.8	39.5	41.7
EBITDA Margin (%)		24.1	15.3	12.8	18.0	26.7
Operating Margin (before GW and except.) (%)		17.9	4.8	-4.2	4.6	13.8
BALANCE SHEET						
Fixed Assets		24.0	51.4	46.4	44.2	42.1
Intangible Assets		0.0	17.2	14.5	13.2	12.1
Tangible Assets		24.0	34.3	31.9	31.0	30.1
Investments		0.0	0.0	0.0	0.0	0.0
Current Assets		57.1	70.0	106.9	108.6	111.0
Stocks		0.0	1.3	1.2	1.5	1.7
Debtors		12.2	12.8	12.2	14.0	15.3
Cash		1.0	6.2	3.6	2.6	5.6
Other		43.9	49.7	89.8	90.4	88.3
Current Liabilities		(13.3)	(8.3)	(9.4)	(7.7)	(8.3)
Creditors		(9.5)	(7.2)	(7.3)	(7.7)	(8.3)
Short term borrowings		(3.8)	(1.1)	(2.0)	0.0	0.0
Long Term Liabilities		(56.7)	(86.8)	(115.8)	(122.2)	(123.8)
Long term borrowings		(22.4)	(52.1)	(50.8)	(57.2)	(58.9)
Other long term liabilities		(34.3)	(34.7)	(65.0)	(65.0)	(65.0)
Net Assets		11.1	26.4	28.1	22.9	20.9
CASH FLOW						
Operating Cash Flow		10.4	6.0	1.8	(0.5)	8.1
Net Interest		(1.5)	(2.8)	(2.4)	(3.1)	(3.3)
Tax		(1.3)	5.4	0.4	0.5	0.1
Capex		(3.8)	(1.7)	(2.6)	(2.3)	(2.5)
Acquisitions/disposals		(2.6)	(34.5)	0.0	0.0	0.0
Financing		0.5	11.2	0.6	0.0	0.0
Dividends		(2.0)	0.0	0.0	0.0	(1.1)
Net Cash Flow		(0.3)	(21.8)	(2.3)	(5.4)	1.4
Opening net debt/(cash)		24.9	25.2	47.0	49.2	54.6
HP finance leases initiated		0.0	0.0	0.0	0.0	0.0
Other		(0.0)	0.0	0.0	(0.0)	(0.0)
Closing net debt/(cash)		25.2	47.0	49.2	54.6	53.2

Source: Company reports, Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting. Edison is authorised and regulated by the [Financial Conduct Authority](#). Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com

DISCLAIMER

Copyright 2018 Edison Investment Research Limited. All rights reserved. This report has been commissioned by Medserv and prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Investment Research Pty Ltd (Corporate Authorised Representative (1252501) of Myonlineadvisers Pty Ltd (AFSL: 427484)) and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research. Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. FTSE International Limited ("FTSE") © FTSE 2018. "FTSE®" is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE's express written consent.